RenovoRx annual stock-based compensation
2020
2021
2022
2023
2024
2025
RenovoRx Stock-Based Compensation Growth & History (RNXT)
RenovoRx's stock-based compensation was $1.3M for fiscal 2025.
View full RenovoRx company overviewRenovoRx annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.3M | $93,000 | +7.92% |
| 2024 | 2024-12-31 | $1.2M | $96,000 | +8.91% |
| 2023 | 2023-12-31 | $1.1M | $434,000 | +67.39% |
| 2022 | 2022-12-31 | $644,000 | $497,000 | +338.10% |
| 2021 | 2021-12-31 | $147,000 | $114,000 | +345.45% |
| 2020 | 2020-12-31 | $33,000 | — | — |
RenovoRx quarterly stock-based compensation
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $570,000 | $225,000 | +65.22% |
| Q1 2026 | 2026-03-31 | $317,000 | $29,000 | +10.07% |
| Q4 2025 | 2025-12-31 | $285,000 | $33,000 | +13.10% |
| Q3 2025 | 2025-09-30 | $349,000 | $94,000 | +36.86% |
| Q2 2025 | 2025-06-30 | $345,000 | $101,000 | +41.39% |
| Q1 2025 | 2025-03-31 | $288,000 | −$135,000 | −31.91% |
| Q4 2024 | 2024-12-31 | $252,000 | $31,000 | +14.03% |
| Q3 2024 | 2024-09-30 | $255,000 | $16,000 | +6.69% |
| Q2 2024 | 2024-06-30 | $244,000 | −$13,000 | −5.06% |
| Q1 2024 | 2024-03-31 | $423,000 | $62,000 | +17.17% |
| Q4 2023 | 2023-12-31 | $221,000 | $57,000 | +34.76% |
| Q3 2023 | 2023-09-30 | $239,000 | $96,000 | +67.13% |
| Q2 2023 | 2023-06-30 | $257,000 | $88,000 | +52.07% |
| Q1 2023 | 2023-03-31 | $361,000 | $193,000 | +114.88% |
| Q4 2022 | 2022-12-31 | $164,000 | $38,000 | +30.16% |
| Q3 2022 | 2022-09-30 | $143,000 | $137,000 | +2283.33% |
| Q2 2022 | 2022-06-30 | $169,000 | $162,000 | +2314.29% |
| Q1 2022 | 2022-03-31 | $168,000 | $160,000 | +2000.00% |
| Q4 2021 | 2021-12-31 | $126,000 | — | — |
| Q3 2021 | 2021-09-30 | $6,000 | −$1,000 | −14.29% |
| Q2 2021 | 2021-06-30 | $7,000 | — | — |
| Q1 2021 | 2021-03-31 | $8,000 | — | — |
| Q3 2020 | 2020-09-30 | $7,000 | — | — |
RenovoRx stock-based compensation trends
Over the last five fiscal years, RenovoRx's stock-based compensation increased from $33,000 to $1.3M, a change of $1.2M. The latest reported quarter, Q2 2026, shows $570,000.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review RenovoRx source filings ↗